Cargando…

Function of PD-L1 in antitumor immunity of glioma cells

Human glioma is a highly fatal tumor with a significant feature of immune suppression. The functions of PD-L1 refer to co-simulation and immune regulation. To investigate expression and functional activity of PD-L1 in human glioma cell in vivo and in vitro. Expressions of PD-L1mRNA and protein in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lou, Yongli, Shi, Jin, Guo, Dewei, Qureshi, Ahmad Kaleem, Song, Laijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5415119/ https://www.ncbi.nlm.nih.gov/pubmed/28490949 http://dx.doi.org/10.1016/j.sjbs.2015.06.025

Ejemplares similares

L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression
por: Huang, Jing, et al.
Publicado: (2022)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
por: Thuru, Xavier, et al.
Publicado: (2022)

AURKA inhibitor-induced PD-L1 upregulation impairs antitumor immune responses
por: Meng, Bi, et al.
Publicado: (2023)

Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity
por: Zhang, Yuankun, et al.
Publicado: (2023)

Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
por: Ding, Ling, et al.
Publicado: (2023)

TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity
por: Ren, Yimeng, et al.
Publicado: (2021)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model
por: Yamaguchi, Izumi, et al.
Publicado: (2019)

IM-6 HVJ-E containing PD-L1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma
por: Sugii, Narushi, et al.
Publicado: (2021)

Tumor-associated neutrophils suppress antitumor immunity of NK cells through the PD-L1/PD-1 axis
por: Sun, Rui, et al.
Publicado: (2020)

Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
por: Verdura, Sara, et al.
Publicado: (2020)

PAS Domain Containing Repressor 1 (PASD1) Promotes Glioma Cell Proliferation Through Inhibiting Apoptosis In Vitro
por: Li, Ruoyan, et al.
Publicado: (2019)

The relationship between autophagy and PD-L1 and their role in antitumor therapy
por: Cui, Yu, et al.
Publicado: (2023)

Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1
por: Lee, Chan-Hyeong, et al.
Publicado: (2022)

Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents
por: Assi, Hikmat H., et al.
Publicado: (2021)

Follicular helper-T cells restore CD8(+)-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
por: Niogret, Julie, et al.
Publicado: (2021)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
por: Qin, Wan, et al.
Publicado: (2020)

A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
por: Barham, Whitney, et al.
Publicado: (2023)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Irreversible electroporation combined with chemotherapy and PD-1/PD-L1 blockade enhanced antitumor immunity for locally advanced pancreatic cancer
por: Ma, Yangyang, et al.
Publicado: (2023)

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
por: Xue, Song, et al.
Publicado: (2017)

Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses
por: Bu, Xia, et al.
Publicado: (2021)

The Prognostic and Therapeutic Value of PD-L1 in Glioma
por: Chen, Ruo Qiao, et al.
Publicado: (2019)

WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function
por: Yoon, Hyun Ju, et al.
Publicado: (2022)

Immunosuppression in Gliomas via PD-1/PD-L1 Axis and Adenosine Pathway
por: Scheffel, Thamiris Becker, et al.
Publicado: (2021)

Spatiotemporal depletion of tumor-associated immune checkpoint PD-L1 with near-infrared photoimmunotherapy promotes antitumor immunity
por: Taki, Shunichi, et al.
Publicado: (2021)

Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer–T cell coculture models
por: Mimura, Kosaku, et al.
Publicado: (2021)

PD-L1-related IncRNAs are associated with malignant characteristics and immune microenvironment in glioma
por: Xia, Zhiwei, et al.
Publicado: (2023)

Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity
por: Guo, Jian, et al.
Publicado: (2018)

Comparison of Immune Checkpoint Molecules PD-1 and PD-L1 in Paired Primary and Recurrent Glioma: Increasing Trend When Recurrence
por: Yu, Wei, et al.
Publicado: (2022)

ISG15 targets glycosylated PD-L1 and promotes its degradation to enhance antitumor immune effects in lung adenocarcinoma
por: Qu, Tongyuan, et al.
Publicado: (2023)

Chlorin e6-associated photodynamic therapy enhances abscopal antitumor effects via inhibition of PD-1/PD-L1 immune checkpoint
por: Gurung, Pallavi, et al.
Publicado: (2023)

PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer
por: Schalper, Kurt A
Publicado: (2014)

A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model
por: Lin, Zhibing, et al.
Publicado: (2019)

Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
por: Fernandez-Rodriguez, Laura, et al.
Publicado: (2023)

Abrine Elicits Liver Carcinoma Immunity and Enhances Antitumor Efficacy of Immune Checkpoint Blockade by Modulating PD-L1 Signaling
por: Zhang, Shaowu
Publicado: (2022)

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
por: Wang, Yichen, et al.
Publicado: (2022)

Disrupting the phase separation of KAT8–IRF1 diminishes PD-L1 expression and promotes antitumor immunity
por: Wu, Yuanzhong, et al.
Publicado: (2023)

Impact of epigenetic reprogramming on antitumor immune responses in glioma
por: McClellan, Brandon L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rsjg4si7g1edo9fjvu55o8fijo